Longeveron (LGVN) Total Current Liabilities (2021 - 2026)
Longeveron (LGVN) posted quarterly Total Current Liabilities of $4.3 million for Q1 2026, up 59.51% year-over-year from $2.7 million in Q1 2025, and up 6.31% quarter-over-quarter from $4.1 million in Q4 2025.
Longeveron (LGVN) Total Current Liabilities (2021 - 2026) Analysis & Trends
Longeveron's Total Current Liabilities history runs 6 years deep, the most recent figure standing at $4.3 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 59.51% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (up 59.51% YoY), while the FY2025 annual figure was $4.1 million, up 58.29% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $4.3 million, up from $4.1 million in the prior quarter.
- The five-year high for Total Current Liabilities was $5.3 million in Q1 2024, with the low at $2.6 million in Q4 2024.
- The 5-year median for Total Current Liabilities is $3.7 million (2023), against an average of $3.8 million.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 79.8% in 2022, then sank 48.56% in 2025.
- Longeveron's Total Current Liabilities stood at $4.9 million in 2022, then retreated by 20.13% to $3.9 million in 2023, then tumbled by 33.61% to $2.6 million in 2024, then surged by 58.29% to $4.1 million in 2025, then gained by 6.31% to $4.3 million in 2026.
- Business Quant data shows LGVN's Total Current Liabilities at $4.3 million in Q1 2026, $4.1 million in Q4 2025, and $4.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 4.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.31 Mn |
| Mar 31, 2026 | 4.35 Mn |
| Dec 31, 2025 | 4.09 Mn |
| Sep 30, 2025 | 4.94 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Mar 31, 2025 | 2.72 Mn |
| Dec 31, 2024 | 2.58 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 3.21 Mn |
| Mar 31, 2024 | 5.30 Mn |
| Dec 31, 2023 | 3.89 Mn |
| Sep 30, 2023 | 3.39 Mn |
| Jun 30, 2023 | 4.08 Mn |
| Mar 31, 2023 | 3.60 Mn |
| Dec 31, 2022 | 4.87 Mn |
| Dec 31, 2021 | 2.71 Mn |